Mutant ATXN1 impacts human and mouse microglia and contributes to cognitive, mood, and motor deficits in SCA1 mice

Insights

Mutant ATXN1 in brain immune cells (microglia) drives Spinocerebellar ataxia type-1 (SCA1) disease and symptoms. Removing this mutant ATXN1 from microglia improves SCA1 mouse brain pathology and behavior.

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Microglia, the brain's immune cells, are implicated in neurodegeneration.
  • The specific role of intrinsic microglial factors in diseases like Spinocerebellar ataxia type-1 (SCA1) is unclear.
  • SCA1 is a neurodegenerative disease caused by expanded CAG repeats in the ATXIN1 gene.

Purpose of the Study:

  • To investigate the cell-autonomous effects of mutant ATXIN1 on human microglia.
  • To determine the contribution of microglial mutant ATXIN1 to SCA1 pathogenesis and behavioral deficits.
  • To assess the therapeutic potential of targeting microglial ATXIN1 in SCA1.

Main Methods:

  • Differentiated human microglia from SCA1 patient-derived iPSCs.
  • Utilized a novel conditional SCA1 mouse model (f-ATXN1146Q/2Q) to remove mutant ATXIN1 from microglia and macrophages.
  • Analyzed microglial phenotype, cerebellar pathology, and performed behavioral tests.

Main Results:

  • Mutant ATXIN1 altered human microglia morphology, gene, and protein expression in a cell-autonomous manner.
  • SCA1 microglia showed increased phagocytosis and pro-inflammatory cytokine production.
  • Reducing mutant ATXIN1 in SCA1 mice corrected microglial phenotype, ameliorated Purkinje neuron pathology, reduced astrogliosis, and improved cognitive, mood, and motor deficits.

Conclusions:

  • Mutant ATXIN1 directly impacts microglial phenotype in SCA1.
  • Microglial intrinsic factors contribute significantly to SCA1 pathogenesis.
  • Targeting mutant ATXIN1 in microglia offers a potential therapeutic strategy for SCA1.

Related Concept Videos